Status:
COMPLETED
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Lead Sponsor:
Fox Chase Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer....
Detailed Description
OBJECTIVES: Primary * To assess the degree of fibroblast activation protein (FAP) enzymatic activity at the tumor site in patients with localized pancreatic cancer. Secondary * To explore correlat...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Biopsy-proven adenocarcinoma of the pancreas or pancreatic mass suspicious for pancreatic cancer
- Localized disease
- Scheduled to undergo a resection or exploration of their pancreatic tumor
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 23 2017
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00900016
Start Date
August 1 2007
End Date
June 23 2017
Last Update
September 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States, 19111-2497